High Throughput Genomics Appoints Jerry Zemaitis VP of Commercial Operations

Date Posted: Thursday, August 16, 2007

Print Email to a friend

High Throughput Genomics, Inc. has announced the appointment of Jerry Zemaitis, Ph.D. to the position of vice president of commercial operations.

In this newly created position, Zemaitis will be responsible for forming strategic agreements with academic institutions, cultivating new business partnerships and establishing relationships with distributors in the U.S. and internationally.

Zemaitis joins HTG from Zeta Strategic Consulting, a consulting firm that specializes in business planning and marketing for life sciences and telecommunications companies, where he was founder and principal consultant.

“HTG’s assay technology has immense potential to accelerate the drug discovery process and bring new drugs to market faster,” said Jerry Zemaitis, Ph.D., vice president of commercial operations, HTG. “qNPA enables scientists to refocus on the biology and empowers them to make better decisions with higher confidence.”

Zemaitis earned a B.A. in biology from Rutgers, The State University of New Jersey and did graduate work in biochemistry at the University of Medicine and Dentistry of New Jersey.

Further Information: http://www.htgenomics.com



Related Products

HTG Presents Testing Platform for all Sample Types
The qSeries™ ArrayPlate, is variety of mRNA array products ranging from preconfigured to customized arrays.

HTG Introduces Testing Method for RNA in Fixed Tissue Samples
Using HTG’s qNPA™ technology, researchers can quantitate RNA expression for up to 16 targets simultaneously in FFPE tissue sections without the need for extraction or target amplification.



Related news from our archive

High Throughput Genomics Signs Collaboration Agreement with University of California, San Diego
HTG and UCSD will collaborate to generate arrays to evaluate genes responsible for inflammation and insulin production using HTG’s qNPA™ technology.

HTG’s Technology to be Featured at D2D Conference
Leading pathology researcher at the University of Arizona to discuss benefits of gene expression assay to validate biomarker signatures.

  
Select Biosciences Ltd